Compare Summit Therapeutics Inc (SMMT) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs TKO Group Holdings Inc — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while TKO Group Holdings Inc trades at $195.16 (market cap $14.24B). The key difference: TKO Group Holdings Inc is the larger of the two by market cap, and TKO Group Holdings Inc pays a 1.6% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TKO | |
|---|---|---|
Market Cap | $12.06B | $14.24B |
Sector | Health | Technology |
52-Week High | $26.98 | $224.96 |
52-Week Low | $12.55 | $176.49 |
Enterprise Value | $11.39B | $18.60B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
TKO trades at $195.15, up 3.03% today, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The stock shows robust revenue growth, with Q2 2026 revenue reaching $1.55 billion (up 18% year-over-year, Business Wire, August 3, 2026), and raised full-year guidance. However, a high P/E ratio of 68.33 and mixed quarterly EPS results highlight valuation concerns amid solid operational performance.
The outlook remains positive due to strong media rights and live event momentum, but risks include earnings volatility and competitive pressures. Analyst consensus is strongly bullish with a $228.17 price target, suggesting ~17% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
